Karnataka Institute of Medical Sciences, Hubballi (KIMS, Hubli) is a medical school in Hubballi, India and is affiliated to the Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka. It is one of the oldest government tertiary healthcare centers, and the largest multi-specialty hospital in North Karnataka, recognized by the Medical Council of India. In June 1997, the then Karnataka Medical College was accorded autonomous status and became the Karnataka Institute of Medical Sciences, Hubballi.
This study aims to conduct a comprehensive bibliometric analysis to evaluate the scope and progression of Artificial Intelligence (AI) and Machine Learning (ML) applications in Chronic Rhinosinusitis (CRS) within the field of otorhinolaryngology. Specifically, the objective is to analyse publication trends, collaboration networks, and thematic focus areas in the relevant literature, providing insights into the current state and future directions of AI and ML in managing CRS. A comprehensive literature search was conducted in Scopus and PubMed databases for studies published between 1987 and 2024, focusing on AI and ML in CRS. The bibliometrix package in R was utilized for data analysis, including performance assessment, science mapping, and network analysis to identify key contributors, collaboration patterns, and emerging themes within the research landscape. The analysis of 102 documents shows a consistent annual publication growth of 5.78
Rubinstein–Taybi syndrome (RTS) is a rare genetic disorder characterised by distinctive craniofacial features, broad thumbs and toes, microcephaly and neurodevelopmental delays. We report a case of a late preterm neonate presenting with respiratory distress and multiple dysmorphic features, including broad angulated thumbs and great toes, microcephaly, low-set ears and micrognathia. Neuroimaging showed mild thinning of the corpus callosum, and a small patent foramen ovale was noted on echocardiography. Despite normal genetic testing, a clinical diagnosis of RTS was made based on characteristic phenotypic features. Early supportive care with Kangaroo Mother Care, gradual feeding transitions and multidisciplinary follow-up were initiated. This case underscores the importance of clinical recognition in diagnosing syndromic disorders, particularly when genetic confirmation is inconclusive.
Introduction Heart failure (HF) remains a major global health challenge, particularly in low-resource settings where access to comprehensive cardiac rehabilitation (CR) is limited. Yoga, a culturally contextualised mind-body intervention, holds promise as an adjunctive therapy in CR. The Yoga-EndOmics study aims to evaluate the effects of Yoga-based cardiac rehabilitation (Yoga-CaRe) on gene expression, endothelial function, vascular biomarkers and clinical outcomes in systolic HF, providing mechanistic insights into its potential integration into conventional cardiac rehabilitation.Methods and analysis This is a prospective, randomised, open-label, blinded-endpoint (PROBE) mechanistic trial enrolling 78 patients with HF with reduced ejection fraction (HFrEF). Participants will be randomised in a 1:1 ratio to receive either a structured Yoga-CaRe intervention or enhanced standard care for 3 months. The Yoga-CaRe group will attend 20 supervised sessions with guided home practice involving tailored asanas, pranayama and meditation. Primary outcomes are changes in endothelial-dependent flow-mediated dilation (FMD) and functional exercise capacity at 3 months. Secondary outcomes include changes in arterial compliance and stiffness, circulating biomarkers of endothelial dysfunction, oxidative stress and inflammation, and immediate changes in global gene expression profiles in peripheral blood mononuclear cells following the Yoga-CaRe intervention. Data will be analysed using analysis of covariance (ANCOVA) for between-group comparisons and significant analysis of microarray (SAM) for global gene expression profiles.Ethics and dissemination The study has received ethical clearance from the Institutional Ethics Committee of the SDM College of Medical Sciences and Hospital, India (SDMIEC/2025/1072) and is registered with the Clinical Trials Registry of India. Findings will be disseminated through peer-reviewed journals, scientific conferences and stakeholder engagement platforms to inform future integrative strategies in HF management.Trial registration number CTRI/2023/12/060758
Metastasis, the spread of cancer cells to distant sites, remains a critical challenge in cancer treatment. This process, primarily occurring via hematogenous and lymphatic pathways, significantly contributes to cancer mortality. Sialyl Lewis antigens, such as sLea and sLex, which are commonly found on tumor cells, serve as key ligands for selectins, promoting metastatic dissemination. Abnormal glycosylation, a characteristic of malignant transformation, underscores the importance of glycosyltransferases in synthesizing selectin ligands. In this study, we focused on the role of alpha 2,3-sialyltransferases (ST3GALs) and alpha 3/4 fucosyltransferases (FUTs) in sLex and sLea biosynthesis, revealing potential targets for cancer therapy. By leveraging in silico methods, we investigated the interactions between 23 FDA-approved anticancer drugs and ST3GALs and FUTs. Among the selected drugs, seven drugs demonstrated stronger binding affinity for ST3GALs, notably Alectinib and Palbociclib. We assessed the pharmacokinetic profiles of the drug and employed molecular dynamics simulations to evaluate the binding stabilities of Alectinib and Palbociclib with ST3GALs. This research elucidates the potential repurposing of existing drugs to target glycosylation enzymes involved in metastasis, offering insights into novel therapeutic strategies for combating cancer metastasis.
